Clinical Trials: Cancer Treatment

Kidney Cancer (Clear Cell Carcinoma) Study - L2201

California

A Phase 2 Open Label Extension Study of Conatumumab

A Phase I Study of an MVA Vaccine Targeting P53 in Cancer

A Phase II Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Chondrosarcoma

A Phase II Trial to Evaluate the Activity of Imetelstat (GRN163L) in Patients with Essential Thrombocythemia who Require Cytoreduction and Have Failed or Are Intolerant to Previous Therapy, or who Refuse Standard Therapy

An Open Label, Multi-Center, IRESSA Clinical Access Program of Gefitinib 250 mg (IRESSA) for the Continued Treatment of Patients in the United States who are Currently Benefiting or who have Benefited from Gefitinib Treatment

Determining the Utility of an Assessment Tool for Older Patients with Cancer

PHI-63 NCI #8282: A Phase I Study of Chronically-Dosed, Single Agent ABT-888 in patients with Either BRCA 1/2-Mutated Cancer: Platinum Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer; or Basal Like Breast Cancer

PHI-65, NCI #8808: An Early Phase I Study of ABT-888 in Combination with Carboplatin and Paclitaxel in Patients with Hepatic Renal Dysfunction and Solid Tumors

PHI-66 NCI#8846- Phase I Pharmacokinetic Study of Belinostat for Solid Tumors and Lymphomas in Patients with Varying Degrees of Hepatic Dysfunction

RTOG 0837: Randomized Phase II, Double-Blind, Placebo-Controlled Trial of Conventional Chemoradiation and Adjuvant Temozolomide Plus Cediranib versus Conventional Chemoradiation and Adjuvant Temozolomide Plus Placebo in Patients with Newly Diagnosed Glioblastoma

Fort Lauderdale : Holy Cross Hospital

Kidney Cancer (Clear Cell Carcinoma) Study - L2201

Florida

A7471042

Fort Lauderdale : Holy Cross Hospital

RELEVANCE – RV-FOL-GELARC-0683C

Sarasota : Research Site

Phase 1, Open-label Trial to Determine Safety of OPB-51602 in Subjects With Advanced Cancer

Illinois

1st Line ECOG E4203: Ph II Tx thymidylate synth expr. Prev/Untx/Met Colorect. High TS =Beva/Oxali/CPT-11 VS Beva/Oxali/5-FU/LV. Low/interm TS = Beva, Oxali, 5-FU & LV.

Adjuvant Colon CTSU-CALGB C80702: Ph III 6 vs 12 cycles FOLFOX + Celecoxib Stg III Colon. At least 1 pos lymph node. Completely resected.

Anthracycline Based Chemo MDA 2007-0914:Use of BNP & Troponin I as biomarkers to detect & identify cardiotoxicicty in patients starting new course of Anthracycline-Based chemo

CTSU/NCIC CTG MA.32: Ph III Metformin/Placebo T1-3, N0-3, M0 {If T1c, N0

MDA 2007-0194A (PREDICT) A Multi-Center Study In patients undergoing Anthracycline Based Chemotherapy to Assess the Effectiveness of Using Biomarkers to Detect and Identify Cardiotoxicity and Describe Treatment

Neoadjuvant Rectal SWOG S0713: Ph II Oxal, Xeloda, Cetuximab & RT in Preop tx Stg II-III, Wild-type k-ras Rectal ca.

SWOG S0500 :Ph III Changing Tx versus Maintaining Tx Met HER2 +/- Elevated CTC Levels @ 1st FU.

SWOG S1007 : Ph III Rand Std Adj Endocrine Tx +/- Chemo 1-3 + Nodes, ER/PR +, HER2 Neg, Recurrence Score < 25.

Lexington : UNIVERSITY OF KENTUCKY RESEARCH

UOC 16402 (NCI 8199) (SCI 08-125): Ph II IMC-A12 + mitotane vs mitotane alone.

Kentucky

Cancer: Do You Have Cancer and Problems With Constipation?

Massachusetts

Boston : Research Site

Phase 1, Open-label Trial to Determine Safety of OPB-51602 in Subjects With Advanced Cancer

Michigan

Kidney Cancer (Clear Cell Carcinoma) Study - L2201

Nevada

New York : University Urology Associates

Kidney Cancer (Clear Cell Carcinoma) Study - L2201

New York

PROSTATE CANCER RESEARCH STUDY

Pennsylvania

Nashville : Research Site

Kidney Cancer (Clear Cell Carcinoma) Study - L2201

Tennessee

Phase 1, Open-label Trial to Determine Safety of OPB-51602 in Subjects With Advanced Cancer

Texas

Kidney Cancer (Clear Cell Carcinoma) Study - L2201

Washington